Amalgamated Bank Rain Therapeutics Inc. Transaction History

Amalgamated Bank

  • $12.1 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 06, 2024
SELL
$0.84 - $1.22 $142 - $207
-170 Reduced 9.03%
1,712 $2,000
Q2 2023

Aug 11, 2023
BUY
$1.09 - $9.93 $2,051 - $18,688
1,882 New
1,882 $2,000
Q2 2022

Aug 15, 2022
SELL
$2.21 - $5.56 $5,233 - $13,166
-2,368 Closed
0 $0
Q1 2022

Jun 30, 2022
BUY
$5.07 - $13.68 $12,005 - $32,394
2,368 New
2,368 $12,000

Others Institutions Holding RAIN

# of Institutions
3
Shares Held
122K
Call Options Held
0
Put Options Held
0
View Full List

About Rain Therapeutics Inc.

RAIN Quotes by TradingView
  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email